脓毒症患者脓毒症诱导凝血病的患病率——两项德国多中心随机对照试验的二次分析
该研究为德国脓毒症 competence 网络重症试验组对两项随机对照试验的二次分析,仅纳入符合SEPSIS-3脓毒症标准的患者。在HYPRESS试验267例脓毒症但非脓毒性休克患者中,SIC患病率为22.1%(95%CI 17.5–27.5%);在SISPCT试验1018例患者中,用基于血小板SIC亚评分(PSSC)的简化评分估计SIC患病率为24.2%(95%CI 21.6–26.9%)。HYPRESS中SIC与更高的90天死亡率相关(13.9% vs 26.8%,p=0.027),校正年龄、性别、治疗组和(SIC适配的)SOFA评分后,SIC与生存的负相关仍显著(p=0.011)。SISPCT中PSSC升高与90天死亡率升高相关(PSSC 0:34.4%,PSSC 1:40.5%,PSSC 2:53.3%;p<0.001)。两项试验中,SIC在脓毒症诊断时即已存在或发生在随后4天内。
要点
- 在符合SEPSIS-3的脓毒症患者中,SIC患病率在HYPRESS试验为22.1%(95%CI 17.5–27.5%),在SISPCT试验估计为24.2%(95%CI 21.6–26.9%)。
- HYPRESS试验中,SIC与更高的90天死亡率相关(13.9% vs 26.8%,p=0.027);校正年龄、性别、治疗组和(SIC适配的)SOFA评分后,SIC与生存的负相关仍显著(p=0.011)。
- SISPCT试验中,PSSC升高与90天死亡率升高相关(PSSC 0:34.4%,PSSC 1:40.5%,PSSC 2:53.3%;p<0.001)。
- 两项试验中,SIC在脓毒症诊断时即已存在或发生在随后4天内。
- SIC是脓毒症临床相关并发症,其发生与更高发病率和死亡率相关,应被解读为早期预警信号。
适用人群与场景
- 符合SEPSIS-3脓毒症标准的患者:HYPRESS试验纳入267例脓毒症但非脓毒性休克患者(纳入时),SISPCT试验纳入1018例严重脓毒症或脓毒性休克患者。
诊断标准与关键阈值
- 脓毒症诊断依据第三次国际共识定义(SEPSIS-3)。
- 简化SIC评分基于血小板SIC亚评分(PSSC),PSSC分0、1、2三级。
红旗征与不能漏的情况
- SIC在脓毒症诊断时即已存在或发生在随后4天内,应视为早期预警信号。
研究设计与关键结果
- 研究类型:两项德国多中心随机对照试验(HYPRESS和SISPCT)的二次分析;样本量:HYPRESS 267例,SISPCT 1018例。
- HYPRESS试验中,SIC患病率为22.1%(95%CI 17.5–27.5%);SIC与显著更高的90天死亡率相关(13.9% vs 26.8%,p=0.027)和更高发病率。
- HYPRESS试验中,校正年龄、性别、治疗组和(SIC适配的)SOFA评分的逻辑回归分析证实SIC与生存的负相关(p=0.011)。
- SISPCT试验中,估计SIC患病率为24.2%(95%CI 21.6–26.9%);PSSC升高与90天死亡率升高相关(PSSC 0:34.4%,PSSC 1:40.5%,PSSC 2:53.3%;p<0.001)。
- 两项试验中,SIC在脓毒症诊断时即已存在或发生在随后4天内。
证据类型、等级与局限
- 证据类型:两项随机对照试验的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,SIC是脓毒症临床相关并发症,尽管可能比先前报道的少见,但其发生与更高发病率和死亡率相关,应被解读为早期预警信号。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sepsis and septic shock are frequently accompanied by coagulopathy. Since the sepsis-induced coagulopathy (SIC) score was first described, subsequent studies from Asia revealed a SIC prevalence of 40-60%. In Europe, however, SIC prevalence in patients fulfilling sepsis criteria according to the third international consensus definition (SEPSIS-3) has not yet been evaluated.
METHODS: The Critical Care Trials Group of the German Sepsis Competence Network (SepNet) conducted a secondary analysis of two randomized controlled trials. Only patients fulfilling sepsis criteria according SEPSIS-3 were included in this secondary analysis. In a two step approach, SIC prevalence was determined in 267 patients with sepsis but not septic shock (at the time of inclusion) from the "Effect of Hydrocortisone on Development of Shock Among Patients With Severe Sepsis" (HYPRESS) trial. Then, we estimated SIC prevalence in 1,018 patients from the "Effect of Sodium Selenite Administration and Procalcitonin-Guided Therapy on Mortality in Patients With Severe Sepsis or Septic Shock" (SISPCT) trial using a simplified SIC score based on the platelet-SIC-subscore (PSSC). Study aims were to assess (i) the prevalence of SIC in patients with SEPSIS-3, (ii) the association of SIC with 90-day mortality and morbidity, (iii) the time when patients become SIC positive during the course of sepsis, and (iv) the value of the PSSC for predicting SIC.
RESULTS: In the HYPRESS trial, SIC prevalence was 22.1% (95% confidence interval [CI] 17.5-27.5%). The estimated SIC prevalence in the SISPCT trial was 24.2% (95% CI 21.6-26.9%). In the HYPRESS trial, SIC was associated with significantly higher 90-day mortality (13.9% vs. 26.8%, p = 0.027) and morbidity. Logistic regression analysis adjusted for age, sex, treatment arm, and (SIC-adapted) SOFA score confirmed the negative association of SIC with survival (p = 0.011). In the SISPCT trial, increased PSSCs were associated with higher 90-day mortality (PSSC 0: 34.4%, PSSC 1: 40.5%, PSSC 2: 53.3%; p < 0.001). In both trials, SIC was already present at sepsis diagnosis or occurred during the following 4 days.
CONCLUSIONS: SIC is a clinically relevant complication of sepsis. Although it might be less frequent than previously reported, its occurrence is associated with higher morbidity and mortality and should be interpreted as an early warning sign.
参考来源
- Schmoch T, Möhnle P, Weigand MA, et al. The prevalence of sepsis-induced coagulopathy in patients with sepsis - a secondary analysis of two German multicenter randomized controlled trials. Ann Intensive Care. 2023. PMID: 36635426. doi:10.1186/s13613-022-01093-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。